We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
34 hedge funds and large institutions have $14.3M invested in Crescent Biopharma in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
0.01% less ownership
Funds ownership: 0.51% → 0.49% (-0.01%)
3% less funds holding
Funds holding: 35 → 34 (-1)
10% less capital invested
Capital invested by funds: $15.8M → $14.3M (-$1.51M)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Holders
34
Holders Change
-1
Holders Change %
-2.86%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
6
Closed
5
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
-$31K
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.4K |
| 2 |
IP
Intellectus Partners
San Francisco,
California
|
+$23.4K |
| 3 |
Man Group
London,
United Kingdom
|
+$12.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$12.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.62K |
Top Sellers
| 1 |
D.E. Shaw & Co
New York
|
-$148K |
| 2 |
Two Sigma Advisers
New York
|
-$79.4K |
| 3 |
Two Sigma Investments
New York
|
-$67.6K |
| 4 |
Millennium Management
New York
|
-$49.2K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$37K |
